Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 and Radiotherapy in Metastatic Melanoma
NCT04017897Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Jul 2019
- Primary completion
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, nivolumab in melanoma, sponsored by Yonsei University. Status: unknown.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04017897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04017897.